NCT06143761View on ClinicalTrials.gov

Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

CompletedOBSERVATIONAL

Enrollment

206

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions

Oral Cancer

Interventions

DRUG

PD-1 inhibitor+carboplatin+albumin-bound paclitaxel

A comparative evaluation of patient prognosis between those who received neoadjuvant chemoimmunotherapy-surgery treatment and those who underwent surgery alone.

Trial Locations (1)

510120

Sun Yat-Sen Memorial Hospital, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06143761 - Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer | Biotech Hunter | Biotech Hunter